Biogen bid to revive Tecfidera patents denied by U.S. Supreme Court

Oct. 03, 2022 10:18 AM ETBiogen Inc. (BIIB), VTRSESALY, ESALFBy: Dulan Lokuwithana, SA News Editor

Close up Wooden Law Gavel on the Table


  • Biogen (NASDAQ:BIIB) failed to win reinstatement of a patent on the company's blockbuster multiple sclerosis drug Tecfidera on Monday after the U.S. Supreme Court declined to hear a case in a legal dispute with generic drugmaker Viatris (NASDAQ:VTRS).
  • The justices denied an appeal filed by Biogen (BIIB), leaving intact a lower court ruling that invalidated a key patent related to the 480 mg dose of the treatment.
  • The June 2020 decision helped VTRS subsidiary Mylan Pharmaceuticals to launch a generic version of Tecfidera.
  • Biogen is expanding its pipeline with a focus on Alzheimer’s as generics hurt sales of the multiple sclerosis franchise. For the first six months of 2022, Tecfidera sales dropped ~30% YoY in the U.S.
  • Last week, Biogen (BIIB) and Japanese drugmaker Eisai (OTCPK:ESALF) (OTCPK:ESALY) announced their experimental Alzheimer's medication lecanemab met the main goal in a large late-stage trial.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.